Six drug programs. $250M+ contracted revenue. EU-GMP manufacturing on the former Pfizer campus. One vertically integrated platform built to scale.
The infrastructure is built. The revenue is contracted. The pipeline is advancing.
We have built a pharmaceutical company designed for institutional scale. Six drug development programs. EU-GMP manufacturing. Over $250 million in contracted revenue. A platform validated by multinational partners and positioned for sustainable, diversified growth from API through finished dosage forms.
Brains Bioceutical has built a vertically integrated Life Sciences platform spanning API manufacturing, pharmaceutical drug development, nutraceuticals, and animal health, with clear commercial traction and institutional validation.
The first commercially available market-authorized pharmaceutical-grade CBD Active Pharmaceutical Ingredient, with customer registrations progressing in Brazil and rest of world.
Five-year revenue at risk exceeding $250 million through contracted agreements with multinational pharmaceutical, nutraceutical, and ingredient partners across multiple geographies.
Clear pathway from $20 million to $200 million+ in revenue with strong operating leverage, diversified and de-risked cash flows across pharmaceutical, nutraceutical, and animal health sectors.
Pharma submissions for Opioid Use Disorder and Epilepsy targeted within 24 to 40 months. Pipeline valued at over $1 billion in net present value across six therapeutic indications.
25,000 sq ft EU-GMP certified manufacturing facility on the former Pfizer campus in Kent, UK, with 12.6 tons annual CBD capacity and Schedule 1 Controlled Substances license.
Clear pathway to EBITDA-positive operations with strong gross margin expansion. Diversified, de-risked cash flows across pharmaceutical, nutraceutical, and animal health sectors.
Pharmaceutical-grade Active Pharmaceutical Ingredients. CBD, D9-THC, CBN, CBG solid APIs. EU-GMP certified production. US DMF filed with FDA. Enhanced CBD intermediates through DSM-Firmenich partnership.
Six drug development programs across Opioid Use Disorder, Insomnia, Glaucoma, Inflammation, Osteoarthritis, and Epilepsy. 505(b)(2) and NDA regulatory pathways. Over $1 billion pipeline NPV.
Three-tier commercial strategy. Premium brand through Harrods. Mid-market via Boots and Holland & Barrett. Mass market through Amazon and Day Lewis Pharmacy. Vitabiotics partnership.
Strategic collaborations with leading animal health multinationals. White label OTC strategies in companion animal and equine. CBD API supply for veterinary clinical trials.
Each therapeutic program targets areas with significant clinical demand. Supported by proprietary formulation technology, robust clinical data, and defined regulatory pathways toward market authorization.
From API through finished dosage form. A vertically integrated production capability enabling pharmaceutical-grade drug products across multiple delivery formats.
Pharmaceutical-grade CBD capsules in 400mg, 200mg, 100mg, and 50mg dosage strengths. GMP manufactured with full batch documentation and stability data.
High-concentration pharmaceutical-grade CBD oil formulation. Precision-dosed delivery system for clinical and commercial applications.
Enhanced CBD intermediate formulations developed in collaboration with DSM-Firmenich. Lipid-based, cyclodextrin, and amorphous solid dispersion technologies for improved bioavailability.
Every critical function of the Brains Bioceutical platform has been validated through direct engagement with multinational institutions across manufacturing, distribution, audit, securities, and investment banking.
$20 million five-year convertible loan from DSM-Firmenich, the global leader in nutrition, health, and beauty. Joint development of enhanced CBD intermediate formulations for pharmaceutical and nutraceutical applications.
$20M Convertible InvestmentSupply agreement with Teva, the world's largest generic pharmaceutical company. Validation of Brains Bio's pharmaceutical-grade API quality standards and EU-GMP manufacturing capabilities.
Global Generics LeaderLong-term contracted revenue partnership with Brazil's largest pharmaceutical company for market entry and product registration, unlocking Latin America's largest pharmaceutical market.
Brazil Market AccessAdvanced engagement with The Benchmark Company within the StoneX Group platform (NASDAQ: SNEX), a Fortune 100 financial services firm with a global institutional distribution network.
Fortune 100 PlatformBDO Global for institutional-grade audit and financial reporting across 160+ countries. Lucosky Brookman LLP as U.S. securities counsel for Form F-1 and planned IPO.
IPO ReadinessA summary of progress toward the Company's contemplated listing of its common shares on a U.S. national securities exchange.
Lucosky Brookman LLP engaged in early 2025 to advise the Company on the preparation of its contemplated public listing on a U.S. national securities exchange.
The Company's auditors have completed the 2025 annual audit, a required component of the registration statement filing process.
The Company has engaged a new investment bank to pursue the contemplated listing. This engagement supports capital markets advisory and transaction execution.
The Company's securities counsel is actively preparing a registration statement on Form F-1 for submission to the U.S. Securities and Exchange Commission. Filing is anticipated in the near term.
Following submission, the registration statement will be subject to review by the SEC. This process may involve one or more rounds of comments and amendments prior to the statement being declared effective.
Subject to regulatory approvals, market conditions, and other factors, the Company is pursuing a listing of its common shares on a U.S. national securities exchange. There can be no assurance that the contemplated listing will be completed on the anticipated terms or timeline, or at all.
Forward-Looking Statements. This section contains forward-looking statements within the meaning of applicable securities legislation. These statements relate to future events or the Company's future performance and are based on current expectations and assumptions. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those anticipated.
Nothing in this section constitutes an offer to sell or a solicitation of an offer to buy any securities. Any offering of securities will be made only by means of a prospectus forming part of an effective registration statement.
25,000 sq ft pharmaceutical manufacturing facility at Discovery Park in Kent, United Kingdom. The former Pfizer global research campus. 12.6 tons annual CBD production capacity. Phase II facility expansion completed.
UK Home Office Schedule 1 Controlled Substances license extended to THC and CBN production. Enabling pharmaceutical-grade manufacturing of multiple cannabinoid APIs under full regulatory oversight.
EU-GMP certification for both human and veterinary pharmaceutical manufacturing. MHRA registered site (Site Number 17652846). UK API Manufacturer license 48727.
United States Drug Master File filed with the Food and Drug Administration. Supporting regulatory submissions for drug product applications referencing Brains Bio API.
A differentiated approach to the consumer nutraceutical market spanning premium, mid-market, and mass-market channels with established retail and distribution partnerships.
Premium-positioned CBD wellness products distributed through Harrods and select luxury retail channels. Highest-margin segment with pharmaceutical-grade product differentiation.
Mid-market consumer products through established UK retail pharmacy and health food channels. Vitabiotics partnership providing formulation expertise and distribution infrastructure.
Mass-market channel strategy through Amazon marketplace and Day Lewis Pharmacy network. Volume-driven revenue with established digital and physical retail distribution.
Research programs built on a proprietary platform for the isolation, purification, and formulation of novel Active Pharmaceutical Ingredients. The platform enables development of differentiated therapeutic candidates across multiple indications.
The scientific team includes specialists in pharmaceutical chemistry, formulation science, and regulatory affairs with direct experience navigating FDA, EMA, and MHRA submission pathways.
Each program is supported by robust preclinical and clinical datasets, validated analytical methods, and development milestones aligned with regulatory expectations for market authorization.
Operating within a validated pharmaceutical regulatory framework aligned with FDA, EMA, and MHRA requirements. Regulatory strategy designed to support clinical development and market authorization across multiple jurisdictions.
US Drug Master File filed. Active engagement with FDA on IND-enabling studies. 505(b)(2) pathway for Epilepsy program. NDA submission pathway for Glaucoma/Methazolamide CR.
EU-GMP certification for human and veterinary pharmaceutical manufacturing. MHRA registered manufacturing site. UK API Manufacturer license. Schedule 1 Controlled Substances license for CBD, THC, and CBN.
Customer registrations progressing in Brazil through Prati-Donaduzzi partnership. Regulatory strategy supporting market authorization across North America, Europe, Latin America, and Asia-Pacific.
Multiple value-creating milestones across pharmaceutical, commercial, and regulatory workstreams. A clear line of sight to revenue acceleration, profitability, and institutional capital formation.
Regulatory submissions for Opioid Use Disorder and Epilepsy programs targeted within 24 to 40 months. Phase III initiated for OUD. NDA preparation underway for Glaucoma/Methazolamide CR.
Revenue trajectory from $20 million to $200 million+. Contracted revenue base exceeding $250 million over five years provides visibility and de-risks commercial execution.
Clear pathway to EBITDA-positive operations with expanding gross margins. Diversified cash flows across pharmaceutical API, nutraceuticals, and animal health reducing single-segment concentration risk.
Five-year convertible loan from DSM-Firmenich completed August 2022. Strategic validation from a global leader in nutrition, health, and beauty with $12 billion+ in annual revenue.
Phase II manufacturing facility expansion completed with 11.2 ton production capacity. 25,000 sq ft EU-GMP certified pharmaceutical manufacturing infrastructure at Discovery Park, Kent.
United States Drug Master File filed with the Food and Drug Administration. Regulatory milestone enabling US-based pharmaceutical companies to reference Brains Bio API in drug product applications.
Over $250 million in five-year projected sales revenue secured through binding agreements with multinational pharmaceutical, nutraceutical, and ingredient partners.
UK Home Office Schedule 1 Controlled Substances license extended to include THC and CBN production. Expanding the API portfolio and addressable market for pharmaceutical and clinical applications.
Pharmaceutical pipeline expanded to six clinical programs. Phase III initiated for OUD. POC completed for Inflammation and Osteoarthritis. Pilot PK study completed for Epilepsy 505(b)(2).
Positioned as a platform-stage Life Sciences company with the manufacturing, regulatory, pipeline, and commercial infrastructure required to support institutional capital formation and long-term value creation.
A vertically integrated pharmaceutical platform controlling the full value chain from API production through formulation development, clinical advancement, and commercial distribution.
Contracted revenue exceeding $250 million. EBITDA-positive by FY26. Diversified across pharmaceutical, nutraceutical, and animal health. Multiple regulatory milestones reducing binary risk.
Global addressable market exceeding $200 billion across pharmaceutical, nutraceutical, and animal health sectors. Each division targeting large, established markets with validated commercial pathways.
Senior leadership with deep experience in pharmaceutical development, manufacturing operations, regulatory affairs, capital markets, and global commercial strategy.
A serial entrepreneur with unparalleled foresight and historic firsts in the cannabinoid industry. Established Brains as Brazil's first registered medical cannabis product. Partnered with the largest vitamin distribution company in the UK. Co-founder of Sun Pharm, successfully RTO'd Bevo to create a Canadian LP. A founding member of the CMC and CDPRG.
Former Lead Director of a multi-jurisdictional real estate investment company with over $500 million in assets under management. Former General Counsel and Investment Committee member of a UHNWI Family Office. Founder of Tamar Technologies, a specialty biopharmaceutical venture. Director of InnoCan Pharma (CSE: INNO). Qualified attorney in Gibraltar and England and Wales.
A leading scientist in pharmaceutical, biotech, and healthcare with extensive experience in cannabinoids and CBD. Deep pharmaceutical regulatory and compliance expertise. Former Applied Chemistry Executive at the world's leading pharmaceutical Rx cannabinoid company. Former Global Head of QA for Caligor Rx. Former Director for Fisher Clinical Services.
Experienced commercial executive who has built businesses and led teams across international markets. GSK: CFO of Sub-Saharan Africa, followed by Executive Director of Business Development for the International Region. Over 25 years of experience in the global biopharmaceutical and medical cannabis industry across senior roles at multinational and startup companies. Co-founder of a pharma development company.
Two decades of experience in public affairs, policy development, and government and stakeholder relations across private and public sectors. A proven track record in establishing and maintaining relations with domestic and international governments and stakeholders. Previously served as Director of Policy to the Premier of British Columbia and Senior Director for International Trade.
Chartered Professional Accountant with over 30 years of experience. Former KPMG audit partner on private, government, and public audit clients. A decade of experience in mail order pharmacy and pharmaceutical development. Significant experience with international audit clients and multiple security filing requirements, with a proven track record in hiring top-level executives, restructuring companies, raising capital, and creating cohesive culture.
Proven pharmaceutical leader, entrepreneur, and drug developer. Founded Caelum Biosciences and led from inception through acquisition by AstraZeneca (2017 to 2021). Built six pharmaceutical companies leading to multiple acquisitions and one out-license for a late-stage company. GSK Anti-infective US Marketing Head. CEO of GSK South Africa (Pharma Trade President). Experience working in Brazil, UK, US, and South Africa.
Over 25 years of experience leading clinical programs. Delivered 28 programs to IND in neuroscience at Pfizer. Led approval of Incivek at Vertex and built enterprise portfolio management. Built Novartis Research (NIBR) project management office across eight therapeutic areas. Delivered Stresig for HPP and built mRNA business unit at Alexion. Built Mustang Bio portfolio in CAR-T and cell therapy. Caelum COO since inception, leading Phase 2 and Phase 3 study design and execution.
Brains Bioceutical Corp.
Discovery Park, Sandwich
Kent, United Kingdom
ir@brainsbio.com
ir@brainsbio.com
ir@brainsbio.com